BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805.
The Phase 1 study in healthy volunteers will investigate the safety and tolerability of ABBV-0805.
ABBV-0805 is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. The antibody is being evaluated as a disease modifying treatment for Parkinson’s disease.
ABBV-0805 is a result of a strategic research alliance between BioArctic and AbbVie focused on the development of a potential immunotherapy for Parkinson’s disease.
“It is gratifying that our partner AbbVie has started the first clinical trial, a Phase 1 study, with ABBV-0805. We are now looking forward to ABBV-0805 moving forward in the clinical program and developing into a therapy with the potential to provide meaningful advances for patients with Parkinson’s disease,” said Gunilla Osswald, Ph.D., CEO, BioArctic.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
Source: Company Press Release